These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 10172965)

  • 1. Japan's aging population. Implications for healthcare.
    Oliver AJ; Ikegami N; Ikeda S
    Pharmacoeconomics; 1997 Apr; 11(4):306-18. PubMed ID: 10172965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Japan, all-payer rate setting under tight government control has proved to be an effective approach to containing costs.
    Ikegami N; Anderson GF
    Health Aff (Millwood); 2012 May; 31(5):1049-56. PubMed ID: 22566445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Japan's healthcare policy for the elderly through the concepts of self-help (Ji-jo), mutual aid (Go-jo), social solidarity care (Kyo-jo), and governmental care (Ko-jo).
    Sudo K; Kobayashi J; Noda S; Fukuda Y; Takahashi K
    Biosci Trends; 2018 Mar; 12(1):7-11. PubMed ID: 29479017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlling Spending For Health Care And Long-Term Care: Japan's Experience With A Rapidly Aging Society.
    Ikegami N; Rice T
    Health Aff (Millwood); 2023 Jun; 42(6):804-812. PubMed ID: 37276471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Japanese government policy on hospital pharmaceutical profit levels.
    Oliver AJ; Ikegami N; Ikeda S
    J Health Serv Res Policy; 1999 Jan; 4(1):27-32. PubMed ID: 10345563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare technology assessment and the challenge to pharmacoeconomics in Japan.
    Hisashige A
    Pharmacoeconomics; 1997 Apr; 11(4):319-33. PubMed ID: 10172966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reconsidering Japan's underperformance in pharmaceuticals: evidence from Japan's anticancer drug sector.
    Umemura M
    Enterp Soc; 2010; 11(3):560-93. PubMed ID: 20821877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future of Japan's system of good health at low cost with equity: beyond universal coverage.
    Shibuya K; Hashimoto H; Ikegami N; Nishi A; Tanimoto T; Miyata H; Takemi K; Reich MR
    Lancet; 2011 Oct; 378(9798):1265-73. PubMed ID: 21885100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Japan's health care system: containing costs and attempting reform.
    Ikegami N; Campbell JC
    Health Aff (Millwood); 2004; 23(3):26-36. PubMed ID: 15160800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of fertility- and migration-based policy responses to Japan's ageing population.
    Parsons AJQ; Gilmour S
    PLoS One; 2018; 13(12):e0209285. PubMed ID: 30566513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Japanese healthcare: Fostering competition and controlling costs.
    Tiessen JH; Kato K
    Healthc Manage Forum; 2017 Jul; 30(4):175-180. PubMed ID: 28929871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National healthcare spending in the U.S. and Japan: national economic policy and implications for neurosurgery.
    Bean JR
    Neurol Med Chir (Tokyo); 2005 Jan; 45(1):18-24. PubMed ID: 15699616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economics of health care in Japan.
    Ikegami N
    Science; 1992 Oct; 258(5082):614-8. PubMed ID: 1411572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-boundary cancer studies at the University of Tokyo: Current status and outlook for Japan's healthcare system: focus on the response to the aging society.
    Tsuji T
    Jpn J Clin Oncol; 2014 Feb; 44 Suppl 1():i22-27. PubMed ID: 24516207
    [No Abstract]   [Full Text] [Related]  

  • 15. The prospects for reform of the Japanese healthcare system.
    Tokita T
    Pharmacoeconomics; 2002; 20 Suppl 3():55-66. PubMed ID: 12457425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tracking Japan's development assistance for health, 2012-2016.
    Nomura S; Sakamoto H; Sugai MK; Nakamura H; Maruyama-Sakurai K; Lee S; Ishizuka A; Shibuya K
    Global Health; 2020 Apr; 16(1):32. PubMed ID: 32293475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost containment and quality of care in Japan: is there a trade-off?
    Hashimoto H; Ikegami N; Shibuya K; Izumida N; Noguchi H; Yasunaga H; Miyata H; Acuin JM; Reich MR
    Lancet; 2011 Sep; 378(9797):1174-82. PubMed ID: 21885098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hospital reimbursement schemes. Japan's point system and the United States' diagnosis-related groups.
    Abe MA
    Med Care; 1985 Sep; 23(9):1055-66. PubMed ID: 3928986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economic issue of on-line hemodiafiltration within the Japanese medical reimbursement system.
    Takemoto Y; Naganuma T
    Blood Purif; 2013; 35 Suppl 1():74-6. PubMed ID: 23466384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.